Drug updated on 3/28/2024
| Dosage Form | Tablet (oral: 150 mg, 200 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Summary
- Capmatinib (Tabrecta) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.
- Three systematic reviews/meta-analyses were reviewed, providing insights into the frequency, patient characteristics, and outcomes associated with METex14 skipping NSCLC treated by capmatinib.
- Patients with METex14 skipping NSCLC are more likely to be elderly and have adenocarcinoma histology; there was no marked sex or smoking status distribution according to one review.
- In terms of efficacy in first line treatment for these patients, median objective response rate ranged from 50.7% to 68.8% when using targeted therapies like capmatinib compared to lower rates observed with immunotherapy or chemotherapy as per one study's findings.
- Another review suggested that MET-selective tyrosine kinase inhibitors such as capmatinib may become a new standard of care in NSCLC specifically presenting MET exon 14 skipping mutations while also suggesting potential combination treatments involving other TKIs for addressing resistance issues.
- The safety profile of capmatinib appears satisfactory based on another meta-analysis which reported mild adverse events in majority cases; common severe adverse events included lower extremity edema and elevations in alanine aminotransferase and lipase levels but further randomized trials are required for establishing predictive biomarkers for therapy responses among this patient population.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tabrecta (capmatinib) Prescribing Information. | 2022 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. | 2023 | Clinical lung cancer |
| MET-targeted therapies and clinical outcomes: a systematic literature review. | 2022 | Molecular Diagnostics and Therapy |
| MET-targeted therapies for the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. | 2022 | Frontiers in Oncology |